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sitivity and construct validity are warranted, and could be con-
ducted as part of ongoing clinical trials.
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OBJECTIVE: Immunomodulatory drugs have provided hope to
patients with MS. The Nova Scotia provincial health ministry
funds these drugs for patients who are seen by the Dalhousie
Multiple Sclerosis Research Unit (DMSRU), meet predeﬁned 
criteria and attend an education clinic. This study examined the
utilization of these drugs under the provincial program.
METHODS: Data from the DMSRU and pharmacy dispensing
records was accessed from July 1, 1998 to September 16, 2003.
2035 patients attended the clinic of whom 1819 were diagnosed
with MS. Patient and drug therapy characteristics were deter-
mined and compared in those patients receiving immunomodu-
latory drug therapy and those who were not. RESULTS: A total
of 433 patients (326 F) received immunomodulatory drug
therapy. Fifty-nine percent of patients were between 35 and 49
years of age and 56% were classiﬁed as relapsing remitting MS.
Funded patients increased from 98 in 1998 to 365 in 2002. In
2001 the median drug cost/patient was CDN $15,508. The
median number of prescriptions/year was 12.0 (mean 10.7 ±
3.3). 84% of patients received a prescription in 2 ﬁscal years,
while 17% received a prescription in all 5. In 2001, 60% of
patients had a maximum EDSS score of 5 or less. Patients receiv-
ing immunomodulatory drugs were less likely to have EDSS
scores over 6 compared to those not receiving these drugs. The
total expenditure for MS drugs was $4.96 million in 2001/2 with
Rebif® accounting for $1.6 million (CDN). CONCLUSION:
Expenditures grew rapidly for the program (from $0.83 million
in 1998 to $4.96 million in 2001). Most patients were compli-
ant receiving 12 prescriptions/year. Further work is ongoing to
compare patient outcomes and health care costs in those patients
receiving therapy to those who are not.
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OBJECTIVES: The purpose of this study is to estimate the
number of physician visits for a primary complaint of insomnia
and characterize patients with a primary complaint of insomnia,
diagnosis of insomnia and patients utilizing sleep medications.
METHODS: Data was obtained from the 2001 version of the
National Ambulatory Medical Care Survey. Descriptive analyses
were utilized to examine individuals with a primary complaint
of insomnia and/or diagnosed with insomnia. Patient level
weights were utilized to derive national population estimates
from a representative sample. RESULTS: In 2001, there were 1.6
million patient visits for a primary complaint of insomnia. More
females than males (87% vs. 17%), and more Caucasians than
other races (64% vs. 36%) reported insomnia as their primary
complaint. While only 22% of patients complaining of insom-
nia were diagnosed with a sleep disorder, a signiﬁcant number
(79%) were prescribed a medication, including Ambien or
Sonata (26%) and Benadryl (10%). During the same year, 4.8
million patients were diagnosed with a sleep disorder. Patients
were diagnosed by generalist (67%), Psychiatrist (3%) and other
specialist (43%). Yet, only 9% of patients diagnosed with a sleep
disorder had a primary complaint of insomnia upon visiting their
physician. Medications were utilized by 76% of these patients
including Ambien or Sonata (15%) and Benadryl (3%). Only
15% of patients using Ambien or Sonata and only 4% of patients
taking Benadryl were diagnosed with a sleep disorder. CON-
CLUSIONS: This work describes the characteristics of patients
with a primary complaint of insomnia and their resultant diag-
nosis and pharmaceutical treatment. Additionally, we look at
patients diagnosed with insomnia and describe the most common
patient reported reason for their visit and their pharmaceutical
treatment.
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OBJECTIVE: To investigate the sensitivity of cost-effectiveness
(CE) estimates of drug treatment that delays disability progres-
sion in Multiple Sclerosis (MS) to international differences in the
underlying natural history of the disease. METHODS: Simula-
tion model Multiple Sclerosis PharmacoEvaluation Tool (MS-
PEET) was developed to estimate the CE of drug treatment that
delays disability progression in Multiple Sclerosis. MS-PEET was
initially populated with Swedish data on the natural history of
disability progression, measured by the cumulative probability
of patients reaching three disease-speciﬁc severity endpoints
(EDSS 3, 6, 10). Treatment effectiveness is modeled as a reduc-
tion in the probability of EDSS progression. This analysis com-
pares CE estimates based on Nova Scotia natural history data
with estimates based on Swedish data, holding all other variables
constant. Nova Scotia natural history data is from the Dalhousie
Multiple Sclerosis Research Unit (DMSRU). The DMSRU has up
to 25 years of clinical follow-up for 2368 patients. RESULTS:
Preliminary analysis of untreated patients in DMSRU data shows
a less severe natural history course in Nova Scotia relative to
Sweden. The reported cumulative probability of progressing to
severe disability (EDSS ≥ 6) within 10 years of MS-onset is
almost 60 percent less in Nova Scotia than in Sweden. CE esti-
mates based on Nova Scotia natural history data are roughly 
150 percent higher than estimates based on Swedish data. 
CONCLUSION: A less severe MS natural history course limits
potential gains in terms of disability years avoided with treat-
ment. Consequently estimates of cost-effectiveness are likely to
be sensitive to differences in the underlying natural history. MS-
